NICOLE VITULLO
CIK 1196863 · last filed 2025-06-02
NICOLE VITULLO is a corporate insider who has filed 108 SEC Form 4 insider transactions across 23 companies since 2007. The most recent filing, for ESPR, was dated Jun 2, 2025. Across all open-market trades the lifetime net is +$61.2M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $167.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$167.43M
23
108
$61.17M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ESPR | Director | 36,918 | $3.18 | $117.4K | $1.97M | 17 | 2025-06-02 |
| MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | Director | 6,442 | $0.55 | $3.5K | -$67.4K | 14 | 2022-02-07 |
| ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | Director | 0 | — | — | -$5.96M | 21 | 2020-01-29 |
| Vyome Holdings, Inc (OBLN) Delisted | 10%+ Owner | 1,328,657 | $9.15 | $12.16M | $0 | 1 | 2016-10-14 |
| CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | 10%+ Owner | 2,024,203 | — | — | -$6.47M | 1 | 2016-08-03 |
| Celator Pharmaceuticals Inc (CPXX) Delisted | Director | 0 | — | — | $0 | 2 | 2016-07-12 |
| Evoke Pharma Inc (OMED) Delisted | 10%+ Owner | 625,289 | — | — | -$9.70M | 2 | 2016-05-27 |
| SNDX | 10%+ Owner | 761,062 | $20.40 | $15.53M | $0 | 1 | 2016-03-08 |
| Tobira Therapeutics, Inc. (TBRA) Delisted | 10%+ Owner | 38,094 | — | — | $0 | 1 | 2015-05-06 |
| Evofem Biosciences, Inc. (NEOT) Delisted | 10%+ Owner | 8,292 | — | — | $0 | 2 | 2014-12-10 |
| Durata Therapeutics, Inc. (DRTX) Delisted | Director | 22,306 | — | — | $7.06M | 2 | 2014-11-18 |
| Achaogen, Inc. (AKAO) Delisted | 10%+ Owner | 33,890 | — | — | $0 | 1 | 2014-03-17 |
| CADENCE PHARMACEUTICALS INC (CADX) Delisted | 10%+ Owner | 3,019,312 | — | — | $12.57M | 12 | 2014-02-14 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | 10%+ Owner | 1,752,707 | $38.22 | $66.99M | $0 | 1 | 2014-02-04 |
| ALIMERA SCIENCES INC (ALIM) Delisted | 10%+ Owner | 3,585 | $5.54 | $19.9K | $3.97M | 4 | 2014-01-17 |
| TNDM | 10%+ Owner | 318,906 | $22.38 | $7.14M | $0 | 1 | 2013-11-19 |
| VCYT | 10%+ Owner | 3,063,294 | $47.22 | $144.65M | $0 | 1 | 2013-11-04 |
| Tobira Therapeutics, Inc. (RGDO) Delisted | 10%+ Owner | 47,835 | — | — | $3.00M | 1 | 2013-08-28 |
| Ocera Therapeutics, Inc. (TZYM) Delisted | 10%+ Owner | 47,963 | — | — | $8.00M | 1 | 2013-07-16 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | 10%+ Owner | 296,742 | — | — | $18.29M | 12 | 2011-12-22 |
| Clovis Oncology, Inc. (CLVS) Delisted | 10%+ Owner | 35,388 | $0.08 | $2.9K | $12.11M | 1 | 2011-11-21 |
| ZOGENIX, INC. (ZGNX) Delisted | 10%+ Owner | 1,240,417 | $26.68 | $33.09M | $16.40M | 2 | 2011-09-20 |
| Volcano Corp (VOLC) Delisted | 10%+ Owner | 61,860 | — | — | $0 | 2 | 2008-06-09 |
Recent Filings
108 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-02 | ESPR | Grant (A) | — | $0 | EDGAR |
| 2024-05-24 | ESPR | Grant (A) | — | $0 | EDGAR |
| 2023-06-16 | ESPR | Grant (A) | +5,150 | $0 | EDGAR |
| 2022-05-27 | ESPR | Grant (A) | — | $0 | EDGAR |
| 2022-02-07 | MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | Grant (A) | +2,750 | $0 | EDGAR |
| 2021-05-28 | ESPR | Grant (A) | +12,376 | $0 | EDGAR |
| 2021-03-16 | MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | Mixed | −632,366 | -$67.4K | EDGAR |
| 2021-01-20 | MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-11-06 | MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-05-29 | ESPR | Grant (A) | +6,106 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.